Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474745 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL20982597 | 0.91 | ALDH1A1 (0.83) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL9611665 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL2242681 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL517706 | 0.85 | MEN1 (0.77) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL12936428 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL338550 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL20982642 | 0.83 | KDM4E (0.71) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL2951391 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ERAB9ANPC1PKM | |
| SCHEMBL13053096 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ERAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082589-A | Preparation method and application of metal nitrogen heterocyclic carbene functionalized covalent organic framework material | 中国科学院福建物质结构研究所 | 2023-05-09 | — | — | CN | disclosed |
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | THE GENERAL HOSPITAL CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | THE GENERAL HOSPITAL CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | THE BROAD INSTITUTE, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | THE BROAD INSTITUTE, INC. | 2016-03-17 | — | — | US | disclosed |
| WO-2014179303-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYNDROME AND ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2731953-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Abbvie Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8716297-B2 | Chemical entities to be used for Wee1 inhibition for the treatment of cancer | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2013012681-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | ABBOTT LABORATORIES (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-0194529-B1 | USE OF 2-(AMINOPHENYL)-BENZIMIDAZOLE DERIVATIVES IN THE PREPARATION OF MEDICAMENTS FOR COMBATING MALIGN AND NON-MALIGN PROLIFERATIVE AS WELL AS AUTO-IMMUNE DISEASES AND IN IMMUNOSUPPRESSION IN TRANSPLANTATIONS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1992-09-02 | — | — | EP | disclosed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | disclosed |
| EP-0194529-A2 | Use of 2-(aminophenyl)-benzimidazole derivatives in the preparation of medicaments for combating malign and non-malign proliferative as well as auto-immune diseases and in immunosuppression in transplantations | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | WEE1, WEE2, CCNE1 | ALDH1A1 1453/4885KDM4E 441/4885RAB9A 2348/4885 |
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | APP, UPF1, BACE1 | ALDH1A1 3698/4885KDM4E 2655/4885RAB9A 2552/4885 |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | APP, UPF1, GAP43 | ALDH1A1 3791/4885KDM4E 3396/4885RAB9A 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.